Table 4.
Risk factors for the occurrence of MAS
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| p | OR | 95% CI | p | OR | 95% CI | ||
| Age | 0.138 | 0.955 | 0.898–1.015 | ||||
| Sex | 0.784 | 1.366 | 0.147–12.677 | ||||
| LDH | 0.009 | 1.005 | 1.001–1.008 | ||||
| PLT | 0.035 | 0.992 | 0.984–0.999 | ||||
| IL-2R | 0.002 | 1.002 | 1.001–1.003 | 0.002 | 1.003 | 1.001–1.007 | |
| SUVmax of the spleen > 3.55 | 0.004 | 19.170 | 2.182–2528.558 | ||||
| TLGtotal of LNs > 248,040 | 0.013 | 15.000 | 1.752–128.391 | ||||
| MLVtotal of LNs > 62.2 | 0.002 | 62.000 | 4.529–848.704 | 0.042 | 27.375 | 1.117–123,080.200 | |
Both TLGtotal and MLVtotal of LNs were calculated from the patients with hypermetabolic lymph nodes (n = 38). All laboratory variables were included in logistic regression, and only the results with p < 0.1 were listed here
LDH lactate dehydrogenase, PLT platelet, IL-2R interleukin-2 receptor, SUV standardized uptake value, LN lymph node, TLG total lesion glycolysis, MLV metabolic lesion volume, MAS macrophage activation syndrome